BIOGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31)
BIOGEN INC. (BIIB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) of 450.00% for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-04.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm · last filed 2011-02-04
- BIOGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2010 was 450.00%, a 4.26% decline from fiscal 2009.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2009 was 470.00%, a 7.84% decline from fiscal 2008.
- BIOGEN INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2008 was 510.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) 12 month |
|---|---|
| 2010-12-31 | 450.00% 10-K · filed 2011-02-04 |
| 2009-12-31 | 470.00% 10-K · filed 2011-02-04 |
| 2008-12-31 | 510.00% 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |